Drug Type Small molecule drug |
Synonyms N-(2-Methoxyethyl)-6-methyl-N-[(3-methyl-2-thienyl)methyl]-2-oxo-1,2-dihydropyridine-4-carboxamide |
Target |
Action inhibitors |
Mechanism LAMP-1 inhibitors(Lysosome-associated membrane glycoprotein 1 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
RegulationOrphan Drug (European Union) |
Molecular FormulaC16H20N2O3S |
InChIKeyBBEZNLRXWCUHAJ-UHFFFAOYSA-N |
CAS Registry1257155-76-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Polyglucosan Body Disease, Adult Form | Preclinical | Israel | 14 Aug 2023 | |
Glycogen Storage Disease Type IV | Preclinical | United States | 09 Aug 2023 |